CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
“We are really excited about this transaction, which we believe creates value for our shareholders and represents an outstanding opportunity for our future growth, positioning DiaSorin and Luminex as a unique combination of diagnostic specialists,” Carlo Rosa, CEO of DiaSorin Group, said in a press statement. “Luminex perfectly fits with our strategy to grow our positioning in the molecular diagnostics space, to broaden our presence in the U.S., and to create additional value through life science offerings.”
The transaction is expected to close within the third quarter of this year.
Pages: 1 2